ticlopidine has been researched along with Chronic Hepatitis B in 4 studies
Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Built on these observations, a recent preclinical study took advantage of a previously established hepatitis B virus (HBV) transgenic mouse model of immune-mediated chronic hepatitis that progresses to hepatocellular carcinoma (HCC), to demonstrate that clinically achievable doses of the anti-platelet drugs aspirin and clopidogrel - administered continuously after the onset of liver disease - can prevent hepatocarcinogenesis and greatly improve overall survival." | 3.79 | Anti-platelet therapy in the prevention of hepatitis B virus-associated hepatocellular carcinoma. ( Guidotti, LG; Iannacone, M; Sitia, G, 2013) |
| "Recurrence of hepatocellular carcinoma (HCC) with unsatisfactory survival is common after surgical resection." | 1.43 | Antiplatelet Therapy is Associated with a Better Prognosis for Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma after Liver Resection. ( Chao, Y; Chen, CC; Chen, TJ; Hu, YW; Huang, YH; Huo, TI; Lee, PC; Lin, HC; Liu, CJ; Su, CW; Wu, JC; Yeh, CM, 2016) |
| "Treatment with aspirin and clopidogrel during the chronic phase of the disease diminished the number of intrahepatic HBV-specific CD8(+) T cells and HBV-nonspecific inflammatory cells, the severity of liver fibrosis, and the development of HCC." | 1.38 | Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B. ( Aiolfi, R; Chisari, FV; Di Lucia, P; Esposito, A; Fiocchi, A; Guidotti, LG; Iannacone, M; Mainetti, M; Mingozzi, F; Ruggeri, ZM; Sitia, G, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sitia, G | 2 |
| Iannacone, M | 2 |
| Guidotti, LG | 2 |
| Lee, PC | 1 |
| Yeh, CM | 1 |
| Hu, YW | 1 |
| Chen, CC | 1 |
| Liu, CJ | 1 |
| Su, CW | 1 |
| Huo, TI | 1 |
| Huang, YH | 1 |
| Chao, Y | 1 |
| Chen, TJ | 1 |
| Lin, HC | 1 |
| Wu, JC | 1 |
| Aiolfi, R | 1 |
| Di Lucia, P | 1 |
| Mainetti, M | 1 |
| Fiocchi, A | 1 |
| Mingozzi, F | 1 |
| Esposito, A | 1 |
| Ruggeri, ZM | 1 |
| Chisari, FV | 1 |
| Greenhill, C | 1 |
4 other studies available for ticlopidine and Chronic Hepatitis B
| Article | Year |
|---|---|
Anti-platelet therapy in the prevention of hepatitis B virus-associated hepatocellular carcinoma.
Topics: Animals; Aspirin; Blood Platelets; Carcinoma, Hepatocellular; CD8-Positive T-Lymphocytes; Cell Proli | 2013 |
Antiplatelet Therapy is Associated with a Better Prognosis for Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma after Liver Resection.
Topics: Adult; Aged; Aspirin; Carcinoma, Hepatocellular; Clopidogrel; Disease-Free Survival; Female; Gastroi | 2016 |
Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B.
Topics: Analysis of Variance; Animals; Aspirin; Carcinoma, Hepatocellular; CD8-Positive T-Lymphocytes; Clopi | 2012 |
Hepatocellular carcinoma: could antiplatelet drugs be used to prevent HBV-associated hepatocellular carcinoma?
Topics: Animals; Carcinoma, Hepatocellular; Chemoprevention; Clopidogrel; Disease Models, Animal; Disease Pr | 2012 |